Levetiracetam Level
This biomarker measures the concentration of levetiracetam, an anticonvulsant medication, in the blood to ensure it is within the therapeutic range.
Levetiracetam level monitoring ensures the drug is within the therapeutic range of 12–46 mg/L.
Key facts at a glance
- Units
- mg/L
- Clinical utility
- monitoring
- Result kind
- quantitative
- FDA-cleared
- Roche Levetiracetam, Chromsystems Levetiracetam
Levetiracetam is a medication primarily used in the management of epilepsy and other seizure disorders. Monitoring its level in the blood is crucial to ensure it is within the therapeutic range, which is typically between 12–46 mg/L.
Levels below the therapeutic range may result in inadequate seizure control, while levels above may increase the risk of adverse effects. Regular monitoring helps in adjusting the dosage as needed.
The measurement of levetiracetam levels is typically done through blood tests. It is important for patients to follow their healthcare provider's instructions regarding medication and testing schedules.
Frequently asked questions
Why is it important to monitor levetiracetam levels?
What happens if my levels are too low or too high?
Sources
- 1Levetiracetam MonitoringSource
- 2
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy